B of A Securities Maintains Buy on Abbott Laboratories, Lowers Price Target to $120

Benzinga Newsdesk www.benzinga.com Negative 45.0%

Neg 45% Neu 0% Pos 0%

B of A Securities analyst Travis Steed maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $150 to $120.